ARTICLE | Company News

Fujirebio, Laboratory Corp. of American Holdings, Abbott sales and marketing update

January 23, 2012 8:00 AM UTC

LabCorp launched the Risk of Ovarian Malignancy Algorithm (ROMA) stratification tool in the U.S. The tool combines Fujirebio's HE4 enzyme immunoassay (EIA) and Abbott's CA125II blood test results to aid in assessing the risk of finding malignant epithelial ovarian cancer on surgery in women over 18 years of age presenting with a pelvic mass for whom surgery is planned and who have not yet been referred to an oncologist. ...